Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Alexandra B. Forman"'
Autor:
Clare F. Malone, Minjee Kim, Gabriela Alexe, Kathleen Engel, Alexandra B. Forman, Amanda Robichaud, Amy Saur Conway, Amy Goodale, Ashleigh Meyer, Delan Khalid, Allen Thayakumar, John M. Hatcher, Nathanael S. Gray, Federica Piccioni, Kimberly Stegmaier
Publikováno v:
Cancer Research. 83:285-300
Aberrant RAS/MAPK signaling is a common driver of oncogenesis that can be therapeutically targeted with clinically approved MEK inhibitors. Disease progression on single-agent MEK inhibitors is common, however, and combination therapies are typically
Autor:
Kimberly Stegmaier, Francisca Vazquez, Todd R. Golub, David E. Root, Scott T. Younger, Joseph D. Mancias, Volker Hovestadt, Nancy Dumont, Brenton R. Paolella, Joshua M. Dempster, Amy Saur Conway, Amanda L. Robichaud, Miljan Kuljanin, Alfredo Gonzalez, Mai Abdusamad, Michael V. Rothberg, Alexandra B. Forman, Guillaume Kugener, Neekesh V. Dharia, Clare F. Malone
NXT2 expression is associated with NXT1 dependency
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89b3b0cf92ac2514acd3f0a02dca1932
https://doi.org/10.1158/2159-8290.22539455.v1
https://doi.org/10.1158/2159-8290.22539455.v1
Autor:
Kimberly Stegmaier, Francisca Vazquez, Todd R. Golub, David E. Root, Scott T. Younger, Joseph D. Mancias, Volker Hovestadt, Nancy Dumont, Brenton R. Paolella, Joshua M. Dempster, Amy Saur Conway, Amanda L. Robichaud, Miljan Kuljanin, Alfredo Gonzalez, Mai Abdusamad, Michael V. Rothberg, Alexandra B. Forman, Guillaume Kugener, Neekesh V. Dharia, Clare F. Malone
CRISPR guide sequences
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33f5c15a72ce13e9594b29f8a9df403d
https://doi.org/10.1158/2159-8290.22539446.v1
https://doi.org/10.1158/2159-8290.22539446.v1
Autor:
Kimberly Stegmaier, Francisca Vazquez, Todd R. Golub, David E. Root, Scott T. Younger, Joseph D. Mancias, Volker Hovestadt, Nancy Dumont, Brenton R. Paolella, Joshua M. Dempster, Amy Saur Conway, Amanda L. Robichaud, Miljan Kuljanin, Alfredo Gonzalez, Mai Abdusamad, Michael V. Rothberg, Alexandra B. Forman, Guillaume Kugener, Neekesh V. Dharia, Clare F. Malone
Cancer dependency maps, which use CRISPR/Cas9 depletion screens to profile the landscape of genetic dependencies in hundreds of cancer cell lines, have identified context-specific dependencies that could be therapeutically exploited. An ideal therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c0222ac2a2c6c22d60bba9034ffb48f
https://doi.org/10.1158/2159-8290.c.6549098.v1
https://doi.org/10.1158/2159-8290.c.6549098.v1
Autor:
Kimberly Stegmaier, Federica Piccioni, Nathanael S. Gray, John M. Hatcher, Allen Thayakumar, Delan Khalid, Ashleigh Meyer, Amy Goodale, Amy Saur Conway, Amanda Robichaud, Alexandra B. Forman, Kathleen Engel, Gabriela Alexe, Minjee Kim, Clare F. Malone
Supplemental Figures S1-S6 and Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8650dac4e203c2c17f3354686bcb280e
https://doi.org/10.1158/0008-5472.22432890.v1
https://doi.org/10.1158/0008-5472.22432890.v1
Autor:
Kimberly Stegmaier, Federica Piccioni, Nathanael S. Gray, John M. Hatcher, Allen Thayakumar, Delan Khalid, Ashleigh Meyer, Amy Goodale, Amy Saur Conway, Amanda Robichaud, Alexandra B. Forman, Kathleen Engel, Gabriela Alexe, Minjee Kim, Clare F. Malone
Supplementary Table S1 STARS Scores
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e95c614243a00ada2f95013e5ab334c
https://doi.org/10.1158/0008-5472.22432887.v1
https://doi.org/10.1158/0008-5472.22432887.v1
Autor:
Kimberly Stegmaier, Federica Piccioni, Nathanael S. Gray, John M. Hatcher, Allen Thayakumar, Delan Khalid, Ashleigh Meyer, Amy Goodale, Amy Saur Conway, Amanda Robichaud, Alexandra B. Forman, Kathleen Engel, Gabriela Alexe, Minjee Kim, Clare F. Malone
Aberrant RAS/MAPK signaling is a common driver of oncogenesis that can be therapeutically targeted with clinically approved MEK inhibitors. Disease progression on single-agent MEK inhibitors is common, however, and combination therapies are typically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30ca8788e88103e75b8444dc85940ca7
https://doi.org/10.1158/0008-5472.c.6514260.v1
https://doi.org/10.1158/0008-5472.c.6514260.v1
Autor:
Joshua M. Dempster, Neekesh V. Dharia, Mai Abdusamad, David E. Root, Volker Hovestadt, Francisca Vazquez, Kimberly Stegmaier, Clare F. Malone, Amanda L. Robichaud, Amy Saur Conway, Alfredo Gonzalez, Todd R. Golub, Alexandra B. Forman, Joseph D. Mancias, Guillaume Kugener, Brenton R. Paolella, Miljan Kuljanin, Michael V. Rothberg, Scott T. Younger, Nancy Dumont
Publikováno v:
Cancer Discovery. 11:2282-2299
Cancer dependency maps, which use CRISPR/Cas9 depletion screens to profile the landscape of genetic dependencies in hundreds of cancer cell lines, have identified context-specific dependencies that could be therapeutically exploited. An ideal therapy
Autor:
Clare F. Malone, Minjee Kim, Gabriela Alexe, Alexandra B. Forman, Amanda Robichaud, Amy Saur Conway, Amy Goodale, John M. Hatcher, Nathanael S. Gray, Federica Piccioni, Kimberly Stegmaier
Publikováno v:
Cancer Research. 82:2010-2010
Mutations in the RAS/MAPK pathway are frequent drivers of oncogenesis. Clinically approved MEK inhibitors are effectively used to target RAS-pathway driven cancers in combination with RAF inhibitors in BRAF mutant cancers such as melanoma and non-sma
Publikováno v:
Clinical Oncology Week; 8/5/2024, p179-179, 1p